EICHORCondition: Biochemically Recurrent Prostate Cancer · Sponsor: Bayer
Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer. BCR means that in men who had prostate cancer and were treated by either surgery and/ or radiation therapy, the blood level of a specific protein called PSA rises. PSA is a marker of prostate cancer cells activity. The PSA increase means that the cancer has come back even though conventional imaging such as computed tomography (CT) scans, magnetic resonance imaging (MRI) and bone scans does not show any lesion of prostate cancer. Recently a more sensitive imaging method called prostate-specific membrane antigen \[PSMA\] positron emission tomography \[PET\]) /computed tomography \[CT\]) scan may identify prostate cancer lesions not detectable by conventional imaging. Men with BCR have a higher risk of their cancer spreading to other parts of the body, particularly when PSA levels raised to a certain limit within a short period of time after local therapies. Once the cancer spreads to other parts of the body, it can become even harder to treat. In men with prostate cancer, male sex hormones (also called androgens) like testosterone can help the cancer grow and spread. To reduce androgens levels in these patients, there are treatments that block androgens production in the body called androgen deprivation therapy (ADT). ADT is often used to stop prostate cancer. Another way to stop prostate cancer growth and spread is to block the action of androgen receptors …
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Mayo Clinic Hospital - Phoenix - Cardiology | Phoenix, Arizona, United States | — |
| City of Hope - Duarte Cancer Center | Duarte, California, United States | — |
| USC Norris Comprehensive Cancer Center | Los Angeles, California, United States | — |
| Tower Urology | Los Angeles, California, United States | — |
| UCLA Clark Urology Center | Los Angeles, California, United States | — |
| UCSF Bakar Precision Cancer Medicine Building - Genitourinary | San Francisco, California, United States | — |
| Colorado Urology - St. Anthony Hospital Campus | Lakewood, Colorado, United States | — |
| Northwestern Medicine - Urology | Chicago, Illinois, United States | — |
| Chesapeake Urology Associates - Towson | Baltimore, Maryland, United States | — |
| Sidney Kimmel Comprehensive Cancer Center - Johns Hopkins | Baltimore, Maryland, United States | — |
| Dana-Farber Cancer Institute - Oncology Department | Boston, Massachusetts, United States | — |
| Barbara Ann Karmanos Cancer Institute - Detroit Headquarters | Detroit, Michigan, United States | — |
+ 214 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05794906